In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie, …

Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 (…

HIV-1 entry into CD4 + target cells is mediated by cleaved envelope glycoprotein (Env)
trimers that have been challenging to characterize structurally. Here, we describe the crystal …

… loop is also required for interaction with gp120 V5 and Loop D, and a CDRL1 deletion in
many VRC01-class bNAbs avoids clashes with a glycan linked to Asn 276 (N276) on loop D. …

Therapies to prevent maternal Zika virus (ZIKV) infection and its subsequent fetal
developmental complications are urgently required. We isolated three potent ZIKV-neutralizing …

Molecular understanding of neutralizing antibody responses to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. …

… S7, C and D), consistent with reports that such responses to uncleaved gp140s are typically
V3-dominated (35, 37). Deleting the V3 region consistently reduced the ability of the gp120-…

A major goal of HIV-1 vaccine research is the design of immunogens capable of inducing
broadly neutralizing antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env). Poor …

… D = 100 μM for samples with K D > 100 μM; dashed blue lines show geometric means computed
for the eight germline-reverted Abs or 12 bnAbs for which K D … (16 pM); K D s below this …

… a K d of 21 nM in the absence of PGT121 antibodies to a K d of ∼10 µM in the presence of
excess PGT121 antibodies (Figs. 4A and S6, S7 and Table 2). Together, these observations …